Defining the role of mitochondrial dysfunction in therapy resistance inKRAS mutant colorectal cancer models
Centre for Cancer Research and Cell Biology
Dr E Kerr, Dr I Mills, Dr M Wilson
20 January 2019
Mutant KRAS driven metabolic reprogramming is a key hallmark of cancer, providing the building blocks necessary to support aberrant cancer cell proliferation and is often achieved through rewiring glycolytic, mitochondrial and fatty acid metabolism, reportedly leading to mitochondrial dysfunction.